A health department spokesperson says the PBAC has not decided to cap the number of cost-effectiveness analysis submissions at 32. Yet it has decided that it can only meet its legal obligations under the Act with a cap of 32 in March. Clearly, there is a cap. The question is the basis on which it is applied. …
This circular and semantic argument ends with one conclusion - a submission cap
October 31, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Arrotex launches new PBS-listed combination therapy as gap emerges in hypertension treatments
November 14, 2025 - - Latest News -
Sanofi building an AI-literate organisation through expectations, over experiments
November 14, 2025 - - Latest News -
Prospection says data access and leadership are critical to unlock AI’s potential in healthcare
November 14, 2025 - - Latest News -
The four 'H' words that can help drive the adoption of AI in health
November 14, 2025 - - Latest News -
Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity
November 13, 2025 - - Australian Biotech -
PYC Therapeutics appoints Peter Coleman as new Chair as part of board renewal
November 13, 2025 - - Australian Biotech -
New gene discoveries improve diagnosis of inherited heart disease
November 13, 2025 - - Australian Biotech